Head to Head Contrast: PolyPid (NASDAQ:PYPD) & Cronos Group (NASDAQ:CRON)

PolyPid (NASDAQ:PYPD) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Profitability

This table compares PolyPid and Cronos Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-453.95%	-138.92%
Cronos Group	14.19%	-3.78%	-3.62%

Valuation & Earnings

This table compares PolyPid and Cronos Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$29.02 million	($3.83)	-0.88
Cronos Group	$117.61 million	8.59	$41.08 million	$0.05	52.80

Cronos Group has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for PolyPid and Cronos Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	0	0	5	1	3.17
Cronos Group	0	0	0	0	0.00

PolyPid presently has a consensus price target of $12.40, suggesting a potential upside of 267.95%. Given PolyPid’s stronger consensus rating and higher probable upside, equities analysts clearly believe PolyPid is more favorable than Cronos Group.

Volatility and Risk

PolyPid has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Institutional and Insider Ownership

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Comparatively, 7.3% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About Cronos Group

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.